O6‐methylguanine‐DNA‐methyltransferase (MGMT) promoter methylation serves as a significant molecular marker for assessing the therapeutic efficacy of alkylating agents like temozolomide, which is a first‐line chemotherapy drug for glioma.117. The gene discussed is MGMT; the disease is central nervous system cancer.